PT-141 (Bremelanotide) in Adults 65 and Older: Dosing, Safety, and Transition Considerations

What Is PT-141 and Why Does Age Matter?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors to increase sexual desire. The FDA approved it in August 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized HSDD [1]. Age matters because the drug's clearance depends substantially on renal function, and kidney filtration rate declines by roughly 1% per year after age 40 [2].

Mechanism of Action

Unlike phosphodiesterase inhibitors, bremelanotide does not act on genital vasculature. It binds melanocortin receptors in the hypothalamus, activating dopaminergic pathways linked to desire. This central mechanism means its effects depend on intact neurological signaling, which aging can attenuate through reduced dopamine receptor density and changes in hypothalamic-pituitary axis responsiveness [3].

Why the 65+ Population Presents Unique Challenges

Sexual dysfunction is common in older adults. A 2015 analysis published in the British Journal of Urology International found that 68% of women aged 55 to 79 reported at least one sexual concern [4]. Yet clinical trials for bremelanotide enrolled almost exclusively premenopausal women, leaving the geriatric population largely without trial-level evidence. The RECONNECT trials (Study 301 and Study 302, combined N=1,247) set the foundational efficacy data but included very few participants over 55 and essentially none over 65 [5].

FDA Approval Status and the Off-Label Geriatric Gap

The FDA label for Vyleesi specifies premenopausal women. Using bremelanotide in postmenopausal women or in men aged 65 and older is off-label. This distinction carries real clinical weight.

What the Label Says About Older Adults

The prescribing information states that pharmacokinetic data in patients 65 years and older are limited. The FDA's clinical pharmacology review noted that renal impairment with eGFR below 30 mL/min/1.73 m² results in a 2-fold increase in bremelanotide exposure compared with normal renal function [1]. Given that the mean eGFR in adults aged 70 to 79 is approximately 60 to 69 mL/min/1.73 m² [2], even moderate age-related decline meaningfully raises drug exposure without meeting the threshold that would technically contraindicate use.

Regulatory Perspective on Geriatric Use

The FDA's guidance document on geriatric drug development (Guidance for Industry: Studies in Support of Special Populations) recommends that sponsors include adults 65 and older in clinical trials unless there is a strong scientific reason to exclude them [6]. Bremelanotide's key trials did not meet this standard. This absence of data is itself a clinical signal, prescribers should proceed with extra caution and document the off-label rationale clearly.

Pharmacokinetics in Aging: What Changes and Why

Aging alters the absorption, distribution, metabolism, and excretion of bremelanotide in ways that increase exposure and prolong the drug's effects.

Renal Clearance

Bremelanotide is eliminated primarily through hydrolysis and renal excretion of its metabolites. The Cockcroft-Gault equation predicts that a 70-year-old woman weighing 65 kg with a serum creatinine of 1.0 mg/dL has an estimated creatinine clearance of approximately 45 mL/min, compared with roughly 85 mL/min in a 35-year-old woman with the same weight and creatinine [7]. This reduction in clearance elevates peak and trough concentrations of bremelanotide and its active metabolite, extending both therapeutic and adverse effects.

Volume of Distribution and Body Composition

Older adults have less lean body mass and proportionally more adipose tissue. Bremelanotide has a volume of distribution of approximately 400 liters in young adults. In older patients with higher fat-to-muscle ratios, lipophilic drug redistribution can prolong the drug's half-life from its typical 2.7 hours to a longer effective duration [1]. This pharmacokinetic shift has practical consequences for the 8 to 12 hour blood pressure monitoring window recommended after each dose.

Hepatic Function

Bremelanotide undergoes partial hepatic metabolism. Age-related reductions in hepatic blood flow and CYP enzyme activity, particularly CYP3A4, can slow metabolite clearance. A Journals of Gerontology review of age-related hepatic drug metabolism found that hepatic clearance of drugs with moderate extraction ratios declines by 20 to 40% between ages 40 and 70 [8]. This effect compounds the renal changes described above.

Cardiovascular Safety: The Most Important Risk in Older Adults

The transient blood pressure increase associated with bremelanotide is the safety signal most relevant to geriatric patients.

Blood Pressure Effects in Trial Data

In the RECONNECT trials, bremelanotide produced a mean maximum increase in systolic blood pressure of 6 mmHg and diastolic blood pressure of 4 mmHg, peaking at approximately 4 hours after injection and returning to baseline by 12 hours [5]. The FDA label carries a warning that the drug should not be used in patients with cardiovascular disease, and that blood pressure should be measured before and after each dose in patients with known hypertension [1].

Geriatric Hypertension Prevalence

According to the CDC, approximately 76% of adults aged 65 and older have hypertension [9]. This figure means that the majority of potential geriatric candidates for bremelanotide carry the very condition that complicates its use. A 6 mmHg systolic increase that is clinically benign in a 38-year-old with a baseline of 118/76 mmHg may not be benign in a 72-year-old with a treated baseline of 138/84 mmHg and left ventricular hypertrophy.

Cardiac Arrhythmia and QTc

The FDA pharmacology review noted no significant QTc prolongation with bremelanotide at the approved 1.75 mg dose [1]. Nonetheless, older adults with baseline QTc prolongation from concurrent medications such as amiodarone, azithromycin, or methadone should be screened, since the population-level cardiac risk profile in patients over 65 differs substantially from the trial population [10].

Dosing Adjustments and Practical Prescribing in Geriatric Patients

No dose adjustment is specified in the FDA label for age alone, but the pharmacokinetic data strongly support a cautious approach in adults over 65.

Starting Dose Considerations

The standard approved dose is 1.75 mg subcutaneously, self-administered 45 minutes before sexual activity, with a maximum of one dose per 24 hours and no more than one dose per 24-hour period [1]. For geriatric patients with eGFR 30 to 60 mL/min/1.73 m², the FDA does not mandate a formal dose reduction, but given the estimated 30 to 50% increase in AUC at this level of renal impairment, a prescribing clinician could reasonably consider a structured monitoring protocol rather than an immediate reduction:

• Measure blood pressure before the first three doses.
• Assess nausea severity after each of the first three doses and consider pre-treatment with 4 mg ondansetron if nausea exceeds grade 2.
• Review concurrent medications for additive hypotensive risk, including antihypertensives, alpha-blockers for benign prostatic hyperplasia, and nitrates.
• Establish a 12-hour post-dose observation window for the first dose administered in a supervised setting if the patient has any cardiovascular history.

For patients with eGFR below 30 mL/min/1.73 m², the drug is contraindicated per the FDA label due to the 2-fold AUC increase [1].

Polypharmacy Screening

Adults aged 65 and older take an average of 4.5 prescription medications per day according to a 2019 JAMA Internal Medicine analysis of Medicare data [11]. Bremelanotide's interaction profile includes inhibition of intestinal absorption for naltrexone and potential interaction with any drug that alters gastric emptying, since nausea-related vomiting can reduce co-administered oral drug absorption. A full medication reconciliation is non-negotiable before prescribing.

Nausea Management

Nausea occurred in 40% of bremelanotide-treated patients in the RECONNECT trials versus 1.4% placebo [5]. This adverse effect often drives discontinuation. Pre-treatment with 4 mg ondansetron orally 30 minutes before bremelanotide injection reduced nausea severity in an open-label pharmacokinetic substudy, though no large randomized trial has validated this strategy in older adults specifically [12]. Older adults with reduced gastric motility and delayed gastric emptying may experience more pronounced and prolonged nausea.

Transition to Adult Care: Managing Continuity for Geriatric Patients

The phrase "transition to adult care" in a geriatric context refers to patients who were established on bremelanotide in midlife and are now crossing into the 65-and-older age bracket, along with patients transferring care between practitioners, health systems, or telehealth platforms.

What Changes at Age 65

Three clinical realities converge at the geriatric threshold. First, renal function may have declined enough since the last eGFR measurement to change the risk calculus. Second, cardiovascular risk accumulates: a patient who had a baseline Framingham 10-year risk of 8% at age 55 may have a calculated risk exceeding 20% by age 67 without any new diagnoses [13]. Third, concurrent medications change as chronic disease burden increases, raising interaction risk.

A transition-of-care visit should include:

• Current eGFR measurement (not older than 90 days).
• Fasting lipid panel and 10-year ASCVD risk score.
• Review of antihypertensive regimen and current blood pressure control.
• Reassessment of the HSDD diagnosis using validated tools such as the Female Sexual Function Index (FSFI) or the Female Sexual Distress Scale-Revised (FSDS-R) [14].
• Discussion of whether the original indication remains clinically valid and whether alternative therapies such as ospemifene, vaginal estrogen, or testosterone (off-label) may address the patient's symptoms with a different risk profile.

Documentation and Informed Consent

When prescribing bremelanotide off-label in a patient over 65, documentation should explicitly note the off-label nature of the use, the patient's understanding that key trial data did not include her age group, and the specific monitoring plan agreed upon. The American Geriatrics Society's Beers Criteria 2023 update does not list bremelanotide explicitly, but the criteria's general principles about drugs with cardiovascular effects in older adults apply [15].

Telehealth-Specific Transition Considerations

Many patients who receive bremelanotide through telehealth platforms first obtained prescriptions in their late 40s or early 50s. When those patients turn 65 and transition to Medicare, coverage and prescribing context often change. Telehealth prescribers should:

• Confirm that the patient has a primary care or cardiology provider who is aware of the bremelanotide prescription.
• Obtain a written blood pressure log if in-person monitoring is not feasible.
• Reassess annually rather than at the standard renewal intervals used for younger patients.

The American College of Obstetricians and Gynecologists recommends that management of female sexual dysfunction in older women include a multidisciplinary assessment incorporating both hormonal status and psychological factors [16].

Efficacy Evidence: What the Trials Showed and What They Did Not

Understanding bremelanotide's evidence base is necessary before applying it to a population the trials never studied.

RECONNECT Trial Outcomes

The RECONNECT program comprised two identically designed phase 3, randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) enrolling 1,247 premenopausal women with generalized, acquired HSDD [5]. The primary endpoints were change from baseline in the FSDS-R Item 13 score (distress) and change in the number of satisfying sexual events (SSEs) per month.

In the combined analysis, bremelanotide produced a mean reduction of 0.4 points on FSDS-R Item 13 versus 0.2 for placebo (P<0.001) and an increase of 0.7 SSEs per month versus 0.4 for placebo. These are statistically significant but clinically modest effect sizes. The FDA's own advisory committee noted that a minimum clinically important difference had not been formally established at the time of approval [1].

Absence of Geriatric Efficacy Data

No phase 3 trial has enrolled women over 65 with HSDD and tested bremelanotide. A PubMed search for "bremelanotide" AND "elderly" OR "geriatric" OR "older adults" returns fewer than a dozen case reports and pharmacokinetic sub-analyses as of the 2025 literature. The evidence gap is real and should be communicated to patients explicitly.

Comparator Context

Flibanserin (Addyi), the only other FDA-approved drug for HSDD, also lacks strong geriatric trial data. Its DAISY, BEGONIA, and VIOLET trials enrolled premenopausal women with mean ages ranging from 35 to 38 years [17]. Ospemifene, approved for dyspareunia and HSDD in postmenopausal women, has a broader evidence base in older women but acts through a different mechanism (selective estrogen receptor modulation) and carries its own estrogen-related risks [18].

Special Populations Within the 65+ Age Group

Not all geriatric patients carry identical risk. Several subgroups require additional attention.

Adults With Diabetes

Diabetes is present in approximately 29% of adults over 65 per CDC data [19]. Diabetic nephropathy accelerates eGFR decline and raises the probability that a 65-year-old patient already has the moderate renal impairment that elevates bremelanotide exposure. Autonomic neuropathy associated with diabetes may also blunt or alter the central melanocortin response, though no published data quantify this effect.

Adults With Prior Cardiovascular Events

Bremelanotide is contraindicated in patients with cardiovascular disease per the FDA label, defined as known coronary artery disease, heart failure, or prior myocardial infarction or stroke [1]. Given that the prevalence of cardiovascular disease in adults over 65 exceeds 70% [20], this contraindication effectively excludes a large portion of the geriatric population from candidacy.

Patients on Androgen Therapy

Some older women receiving testosterone therapy for low libido may ask whether adding bremelanotide provides incremental benefit. No trial has studied this combination. Testosterone therapy for female sexual dysfunction is itself off-label in the United States, though supported by guideline statements from the Endocrine Society and the International Society for the Study of Women's Sexual Health [21].

Monitoring Protocol for Geriatric Patients on Bremelanotide

A structured monitoring approach reduces the risk of adverse outcomes in older adults.

Baseline Assessment

Before the first dose: measure sitting blood pressure bilaterally, obtain an eGFR within the past 90 days, perform a 12-lead ECG if the patient has any cardiac history, and complete a full medication reconciliation. Confirm the HSDD diagnosis with a validated instrument such as the FSFI [14].

Ongoing Monitoring

After initiation, assess blood pressure before and 4 hours after each of the first three doses. Ask the patient to log SSEs and any adverse effects using a simple diary. Repeat eGFR at 6 months and annually thereafter. If eGFR falls below 30 mL/min/1.73 m², discontinue bremelanotide and document this in the chart [1].

Discontinuation Signals

Stop the drug and reassess if: systolic blood pressure exceeds 160 mmHg at any point during the post-dose monitoring window; nausea leads to vomiting that prevents absorption of other critical medications; the patient reports flushing or hyperpigmentation that causes distress; or the patient reports no improvement in SSEs or distress after six doses [5].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "We recommend against the routine use of pharmacological treatments in women with sexual dysfunction without a thorough evaluation of the underlying cause and contributing factors." [21] This recommendation is especially relevant in geriatric patients, where underlying causes often include treatable conditions such as genitourinary syndrome of menopause, depression, or partner-related factors.